Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.
- Revenue including R&D tax incentive rose 210% to A$4.34 million
- Empax network reached 18 beds across four states, with Sydney secured
- PTSD follow-up data showed approximately 67% remission after 12 months or more
- Net loss widened to A$6.11 million and operating cash outflow increased to A$4.56 million
- A single private health payer accounted for approximately 53% of total revenue
Revenue Growth Meets a Larger Cash Burn
Emyria Limited (ASX:EMD) has increased revenue sharply while remaining firmly in expansion mode. Total revenue including the R&D tax incentive reached A$4.34 million in FY26, up from A$2.99 million, while revenue from services rose to A$4.05 million from A$1.39 million. The result came as the company pushed its Empax psychedelic-assisted treatment network beyond Western Australia and began building insurer-funded activity in several states.
The accounting result was less forgiving. Emyria’s net loss widened to A$6.11 million from A$3.14 million, and operating cash outflow rose to A$4.56 million from A$2.70 million. Cash at year-end stood at A$7.29 million after the company raised A$8 million through an institutional placement and received a further A$1.47 million from equity issues and option exercises during the year.
Empax Network Reaches Four States
Emyria said five clinics were operating or secured across Western Australia, Queensland, Victoria and New South Wales, with total treatment capacity set to reach 18 beds once the Sydney site is activated. The company has also expanded Perth capacity from four rooms to eight and secured exclusive rights to negotiate Empax clinics at current and future Avive Health hospital sites, subject to commercial terms and approvals.
The rollout builds on the national Empax clinic expansion, which was previously reported as taking the model to 18 beds with Sydney nearing launch. Emyria says mature Perth operations provide a guide to the utilisation needed for standalone profitability, while a newly established clinic is expected to take nine to 12 months to reach breakeven and then profitability. That timetable remains a company projection rather than a demonstrated outcome across the wider network.
Insurer Funding and Clinical Evidence Expand
Medibank funding now covers Emyria’s PTSD and Treatment-Resistant Depression programs across clinics in Western Australia, Queensland and Victoria. The Department of Veterans’ Affairs has also created a funding pathway for eligible veterans, while workers’ compensation and other insurers have approved treatment on a case-by-case basis. The arrangement is commercially important, but the annual report says approximately 53% of total revenue came from one private health payer, whose agreements are due for renewal in 2027.
Emyria’s PTSD program produced its strongest longer-term data to date, with approximately 67% of patients remaining in clinical remission at 12 months or more and around 76% recording clinically significant improvement. Its first 10-patient TRD cohort recorded an average 6.8-point fall in QIDS-SR16 depression severity, from 16.8 to 10.0. These are observational, real-world results from small cohorts, have not been peer-reviewed and do not establish efficacy in the same way as a randomised controlled trial.
Going Concern Warning Remains the Central Risk
Stantons gave Emyria an unmodified audit opinion but drew attention to a material uncertainty related to going concern. The auditor pointed to the full-year loss, negative operating cash flow and the company’s A$7.29 million cash balance. Emyria’s directors said downside forecasts indicated the group could continue operating within available cash, but also stated that further funding would be required as necessary.
The annual report therefore presents a company with a more substantial operating platform, but not yet a self-funding one. Its Empax Global Partnership Program adds a second potential revenue stream through clinical trial site services, including work for Psyence Biomed’s Phase IIb adjustment disorder trial. The next test is whether clinic utilisation, payer diversification and sponsor-funded services can grow quickly enough to narrow the gap between commercial momentum and cash consumption.
Bottom Line?
Emyria has built the national platform it set out to create, but the investment case now turns on utilisation, payer renewal and the speed at which revenue can replace external funding.
Questions in the middle?
- Can the newer Empax clinics reach the company’s projected nine-to-12-month path to breakeven?
- How much of the revenue base can Emyria diversify before the key private health agreements come up for renewal in 2027?
- Will larger, independently assessed patient cohorts confirm the durability of the early PTSD and TRD findings?